Johnson & Johnson working on modified vaccines for COVID-19 variants

Kenneth Garger

featured

Mar 19, 2021

1 of 9

A technician works at developing a COVID-19 vaccine candidate at the headquarters of Janssen Pharmaceutica, a Johnson & Johnson subsidiary in Beerse, Belgium on June 17, 2020. — A Johnson & Johnson technician works on a COVID vaccine candidate in Belgium on June 17, 2020. Olivier Matthys/Getty Images

A nurse holds a Johnson & Johnson Covid-19 vaccine at a vaccination center inside the Hilton Chicago O'Hare Airport Hotel in Chicago, Illinois on March 5, 2021. — A nurse holds a J&J COVID vaccine at a shot center inside the Hilton O'Hare Airport Hotel in Chicago on March 5, 2021. KAMIL KRZACZYNSKI/AFP via Getty Images

A Johnson & Johnson campus in Irvine, California. MARK RALSTON/AFP via Getty Images

Rev. Patricia Hailes Fears is given the Johnson & Johnson COVID-19 vaccine at the National Cathedral in Washington, DC on March 16, 2021. — Rev. Patricia Hailes Fears is given the J&J vaccine at the National Cathedral in Washington, DC, on March 16, 2021. Kevin Dietsch/UPI

A man receives the Johnson & Johnson COVID-19 vaccine at the National Cathedral in Washington, DC on March 16, 2021. — A man receives J&J's vaccine at the National Cathedral in Washington, DC, on March 16, 2021. Kevin Dietsch/UPI

J&J covid vaccine — A vial of Johnson & Johnson's COVID vaccine at Northwell Health's South Shore University Hospital in Bay Shore, NY, on March 3, 2021. REUTERS/Shannon Stapleton

American vaccines that transformed public health, prevented millions of illnesses over 250 yearsnypost.com

Latest COVID vaccine may have unexpected health benefit, study suggestsnypost.com

The Anthony Fauci, COVID-19 origins cover-up runs ‘deep’ into our intelligence communitynypost.com

Johnson & Johnson is working to develop modified versions of its COVID-19 vaccine that may be needed to protect against virus variants, a report said.

“We’re working on several next generations of vaccines,” J&J Chief Executive Alex Gorsky said Thursday during an online discussion, according to The Wall Street Journal.

Gorsky expressed optimism that its current vaccine could offer some protection against new COVID-19 strains.

But, he said, “We have to be prepared,” the newspaper reported. “We should prepare for the worst and hope for the best.”

Johnson & Johnson’s single-dose vaccine was approved by the US Food and Drug Administration in late February.

The FDA affirmed J&J’s finding that the vaccine was 66 percent effective overall at warding off moderate and severe COVID-19 cases and 85 percent effective at preventing the most serious infections.

Comments

Powered by RoundtableBuilt on infrastructure designed for real-time media. Learn more at RTB.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy